COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,687 Articles (22,913 medRxiv, 8,774 bioRxiv)

Most recent first Previous |  Page 1847: Articles 18461-18470  | Next

Pooled Surveillance Testing Program for Asymptomatic SARS-CoV-2 Infections in K-12 Schools and Universities
Bi, C., Mendoza, R., Cheng, H.-T., Pagapas, G., Gabutan, E., Khan, N., Hoxie, H., Holmes, K., Gao, N., Lewis, R., Wang, H., Neumann, D., Chan, A., Takizawa, M., Lowe, J., Chen, X., Kelly, B., Asif, A., Barnes, K., Khan, N., May, B., Wright, M., Chowdhury, T., Pollonini, G., Gouda, N., Guy, C., Gordon, C., Ayoluwa, N., Colon, E., Miller-Medzon, N., Jones, S., Hossain, R., Dodson, A., Wang, M., McGaskey, M., Vasileva, A., Seibel, S., Connolly, J., Esposito, M., Kim, J., Lincoln, A. E., Sikka, R., Wyllie, A. L., Berke, E. M., Libien, J., Pincus, M., Premsrirut, P. K.
10.1101/2021.02.09.21251464 — Posted: 2021-02-15
Human liver organoid derived intra-hepatic bile duct cells support SARS-CoV-2 infection and replication and its comparison with SARS-CoV
Lui, V. C.-H., Hui, K. P.-Y., Babu, R. O., Yue, H., Chung, P. H.-Y., Tam, P. K.-H., Chan, M. C.-W., Wong, K. K.-Y.
10.1101/2021.02.10.21251458 — Posted: 2021-02-15
CD8+ T cell responses in COVID-19 convalescent individuals target conserved epitopes from multiple prominent SARS-CoV-2 circulating variants
Redd, A. D., Nardin, A., Kared, H., Bloch, E. M., Pekosz, A., Laeyendecker, O., Abel, B., Fehlings, M., Quinn, T. C., Tobian, A. A.
10.1101/2021.02.11.21251585 — Posted: 2021-02-15
A genetically-informed study disentangling the relationships between tobacco smoking, cannabis use, alcohol consumption, substance use disorders and respiratory infections, including COVID-19
Rosoff, D. B., Yoo, J., Lohoff, F. W.
10.1101/2021.02.11.21251581 — Posted: 2021-02-15
CATALYST trial protocol: A multicentre, open-label, phase II, multi-arm trial for an early and accelerated evaluation of the potential treatments for COVID-19 in hospitalised adults
Veenith, T., Fisher, B. A., Slade, D., Rowe, A., Sharpe, R., Thickett, D. R., Whitehouse, T., Rowland, M., Scriven, J., Parekh, D., Bowden, S. J., Savage, J. S., Richards, D., Bion, J., Kearns, P., Gates, S., on behalf of CATALYST investigators
10.1101/2021.02.10.21251478 — Posted: 2021-02-15
A Comparative Analysis of COVID-19 Physical Distancing Policies in Botswana, India, Jamaica, Mozambique, Namibia, Ukraine, and the United States
Lane, J., Means, A., Bardosh, K., Shapoval, A., Vio, F., Anderson, C., Cushnie, A., Forster, N., Ledikwe, J., OMalley, G., Mawandia, S., Parvez, A., Perrone, L., Mudender, F.
10.1101/2021.02.09.21251433 — Posted: 2021-02-15
Demographic and Hygienic Factors as Predictors of Face Mask Wearing During Covid-19 Pandemic in Malaysia
Looi, K. H., Zhang, S. X., Li, N., Li, J.
10.1101/2021.02.09.21251280 — Posted: 2021-02-15
Mutation N501Y in RBD of Spike Protein Strengthens the Interaction between COVID-19 and its Receptor ACE2
Tian, F., Tong, B., Sun, L., Shi, S., Zheng, B., Wang, Z., Dong, X., Zheng, P.
10.1101/2021.02.14.431117 — Posted: 2021-02-15
Potent, Novel SARS-CoV-2 PLpro Inhibitors Block Viral Replication in Monkey and Human Cell Cultures
Shen, Z., Ratia, K., Cooper, L., Kong, D., Lee, H., Kwon, Y., Li, Y., Alqarni, S., Huang, F., Dubrovskyi, O., Rong, L., Thatcher, G. R., XIONG, R.
10.1101/2021.02.13.431008 — Posted: 2021-02-15
ALG-097111, a potent and selective SARS-CoV-2 3-chymotrypsin-like cysteine protease inhibitor exhibits in vivo efficacy in a Syrian Hamster model
Vandyck, K., Abdelnabi, R., Gupta, K., Jochmans, D., Jekle, A., Deval, J., Misner, D., Bardiot, D., Foo, C. S., Liu, C., Ren, S., Beigelman, L., Blatt, L. M., Boland, S., Vangeel, L., Dejonghe, S., Chaltin, P., Marchand, A., Serebryany, V., Stoycheva, A., Chanda, S., Symons, J. A., Raboisson, P., Neyts, J.
10.1101/2021.02.14.431129 — Posted: 2021-02-15 Discussion: Onsite

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).